Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epirubicin, Cyclophosphamide, and Paclitaxel in Early Breast Cancer
NCT00072319Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Aug 2003
- Primary completion
- Nov 2006
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of epirubicin, cyclophosphamide and paclitaxel in breast cancer, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Absence of grade 3 or higher toxicity up to 5 years. Started Aug 2003; status: completed.
02
Drugs
epirubicincyclophosphamidepaclitaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00072319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00072319.